A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Laekna Limited
Sichuan University
Case Comprehensive Cancer Center
Eastern Cooperative Oncology Group
AIDS Malignancy Consortium
M.D. Anderson Cancer Center
University of Pisa
Zhejiang University
University of California, San Francisco